Saturn V Capital Management LP
Filing Date
Global Rank
#2,393
/ 8,700
▲ 935
Top Industry
Biotechnology
88.1%
Period ended 2 months ago
Filed Aug 14, 2026 · 30d
15 quarters · since Dec 2022
Portfolio Concentration
23 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
11.9%
−0.9 pts
Top 5
47.6%
−1.9 pts
Top 10
75.6%
−1.4 pts
HHI
705
Diversified−29
Portfolio Trend
15 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $697,464,002 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
13 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| ZURA | Zura Bio Ltd | +1,361,159 | 2,101,119 | $12,396,602 | |
| IMMX | Immix Biopharma, Inc. | +964,844 | 4,658,429 | $48,028,402 | |
| XFOR | X4 Pharmaceuticals, Inc | +516,697 | 6,973,343 | $32,565,511 | |
| CADL | Candel Therapeutics, Inc. | +407,098 | 3,303,686 | $34,027,965 | |
| AMLX | Amylyx Pharmaceuticals, Inc. | +274,216 | 4,624,101 | $83,048,853 | |
| OCS | Oculis Holding AG | +168,119 | 684,880 | $9,499,285 | |
| PHVS | Pharvaris N.V. | +112,720 | 1,314,122 | $45,442,338 | |
| ANRO | Alto Neuroscience, Inc. | +93,830 | 182,829 | $4,824,857 | |
| DYN | Dyne Therapeutics, Inc. | +90,884 | 1,057,493 | $23,486,919 | |
| CELC | Celcuity Inc. | +88,414 | 370,318 | $38,742,669 | |
| IRON | Disc Medicine, Inc. | +74,804 | 524,730 | $38,378,752 | |
| PCVX | Vaxcyte, Inc. | +28,382 | 852,914 | $49,579,890 | |
| IKT | Inhibikase Therapeutics, Inc. | +5,611 | 3,869,056 | $7,854,183 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| OVID | Ovid Therapeutics Inc. | −3,503,606 | 663,060 | $1,783,631 | |
| IVVD | Invivyd, Inc. | −2,556,796 | 8,392,288 | $7,318,075 | |
| ALMS | Alumis Inc. | −286,632 | 2,915,443 | $82,040,566 | |
| MNPR | Monopar Therapeutics | −33,650 | 311,976 | $28,885,857 | |
| ABVX | Abivax S.A. | −23,831 | 518,865 | $69,143,949 | |
| JAZZ | Jazz Pharmaceuticals plc | −2,023 | 160,938 | $38,781,229 | |
| No positions match the current search. | |||||
Sold Out
Positions the filer fully exited
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| COGT | Cogent Biosciences, Inc. | 626,635 | $24,119,181 | |
| No positions match the current search. | ||||
23 tracked positions ·
$697,464,002 total
· filing declares
23 positions · $697,467,372
· as of Jun 30, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| AMLX |
Amylyx Pharmaceuticals, Inc.
Healthcare
|
Added | 4,624,101 | $83,048,853 | 11.91% | |
| ALMS |
Alumis Inc.
Healthcare
|
Reduced | 2,915,443 | $82,040,566 | 11.76% | |
| ABVX |
Abivax S.A.
Healthcare
|
Reduced | 518,865 | $69,143,949 | 9.91% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
Added | 852,914 | $49,579,890 | 7.11% | |
| IMMX |
Immix Biopharma, Inc.
Healthcare
|
Added | 4,658,429 | $48,028,402 | 6.89% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Added | 1,314,122 | $45,442,338 | 6.52% | |
| JAZZ |
Jazz Pharmaceuticals plc
Healthcare
|
Reduced | 160,938 | $38,781,229 | 5.56% | |
| CELC |
Celcuity Inc.
Healthcare
|
Added | 370,318 | $38,742,669 | 5.55% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Added | 524,730 | $38,378,752 | 5.50% | |
| CADL |
Candel Therapeutics, Inc.
Healthcare
|
Added | 3,303,686 | $34,027,965 | 4.88% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Added | 6,973,343 | $32,565,511 | 4.67% | |
| MNPR |
Monopar Therapeutics
Healthcare
|
Reduced | 311,976 | $28,885,857 | 4.14% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Added | 1,057,493 | $23,486,919 | 3.37% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
NEW | 1,052,043 | $19,620,601 | 2.81% | |
| ZURA |
Zura Bio Ltd
Healthcare
|
Added | 2,101,119 | $12,396,602 | 1.78% | |
| SGMT |
Sagimet Biosciences Inc.
Healthcare
|
NEW | 1,479,918 | $11,439,766 | 1.64% | |
| OCS |
Oculis Holding AG
Healthcare
|
Added | 684,880 | $9,499,285 | 1.36% | |
| IKT |
Inhibikase Therapeutics, Inc.
Healthcare
|
Added | 3,869,056 | $7,854,183 | 1.13% | |
| VIR |
Vir Biotechnology, Inc.
Healthcare
|
NEW | 770,643 | $7,852,852 | 1.13% | |
| IVVD |
Invivyd, Inc.
Healthcare
|
Reduced | 8,392,288 | $7,318,075 | 1.05% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
Added | 182,829 | $4,824,857 | 0.69% | |
| MSLE |
Satellos Bioscience Inc.
Healthcare
|
Held | 350,000 | $2,721,250 | 0.39% | |
| OVID |
Ovid Therapeutics Inc.
Healthcare
|
Reduced | 663,060 | $1,783,631 | 0.26% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.